1. Targeted immunomodulators for the treatment of moderate-to-severe plaque psoriasis: effectiveness and value : condition update : final evidence report Publication: [Boston, Massachusetts] : Institute for Clinical and Economic Review, August 3, 2018 Subject(s): Immunologic Factors -- therapeutic useImmunomodulationPsoriasis -- drug therapyCertolizumab Pegol -- therapeutic useClinical Trials as TopicCost-Benefit AnalysisImmunologic Factors -- adverse effectsImmunologic Factors -- economicsQuality of LifeTreatment OutcomeHumansUnited States
